Our news

  • 29 August 2017

    "Venture capital, is it obsolete today? I do not think so.." Author's column of Maxim Gorbachev

    "Venture capital, is it obsolete today? I do not think so.." Author's column of Maxim Gorbachev

    Maxim Gorbachev, Managing Partner of RMI Partners: "New technologies make dramatic changes to business. They even reached financing of venture capital companies. Use of crypto-currency has resulted into development of the new mechanism of crowdfunding – Initial Coin Offering (ICO) which is in a way similar to public share placement (IPO). Venture projects utilize blockchain technologies to create and sell digital tokens, thus raising funds from investors. When initially ICO was used as mechanism to develop new crypto-currency instruments such as Ethereum, nowadays ICO serve as a democratic mechanism of fund raising for any project. And this instrument cannot be ignored due to amounts of funds raised this way."   

  • 11 August 2017

    NovaMedica appoints Rustam Iksanov as R&D Vice President

    NovaMedica appoints Rustam Iksanov as R&D Vice President

    Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.

  • 30 May 2017

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

  • 29 May 2017

    NovaMedica appoints Alexander Kuzin as General Director (CEO)

    NovaMedica appoints Alexander Kuzin as General Director (CEO)

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the appointment of Alexander Kuzin to the post of General Director (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017.

  • 21 April 2017

    NovaMedica and Pfizer won the Platinum Ounce award in the nomination Deal of the Year

    NovaMedica and Pfizer won the Platinum Ounce award in the nomination Deal of the Year

    NovaMedica, Russian pharmaceutical company, and Pfizer, one of the leaders of the world biopharmaceutical industry, were recognized as winners of the open professional contest “Platinum Ounce” in the nomination “Deal of the Year” for the long-term partnership agreement which envisages construction of a high-technology pharmaceutical production facility and localization of more than 30 life-saving and essential drugs in Russia. 

  • 19 April 2017

    NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

  • 23 December 2016

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

  • 19 December 2016

    The Expert Opinion. Maxim Gorbachev: "2016 Was a Good Year for Our Venture Biotech Portfolio - 2 IPO and 2 Acquisitions"

    The Expert Opinion. Maxim Gorbachev: "2016 Was a Good Year for Our Venture Biotech Portfolio - 2 IPO and 2 Acquisitions"

    Maxim Gorbachev, Managing Partner: "It’s right time to make the first results of 2016. Let’s have a quick look back on venture biotech market in 2016. How 2016 was for RMI Partners? On the contrary, we have a good year. Two of our portfolio companies have made IPO despite unfavorable market conditions and two - have been acquired at pretty nice valuations."

  • 10 November 2016

    NovaMedica prepares to launch the new drug development laboratories

    NovaMedica prepares to launch the new drug development laboratories

    Russian pharmaceutical company NovaMedica launches R&D laboratories as part of its Technology Center project for the development and pilot production of innovative drugs. The facilities are designed to address the most challenging scientific tasks based on the state-of-the-art platforms incorporating nanotechnologies. The project investment totals $15m.                                                   

  • 03 October 2016

    Four NovaMedica Executives are in the Top-1000 Russian Managers Rating Released by the Managers Association of Russia and Kommersant Publishing House

    Four NovaMedica Executives are in the Top-1000 Russian Managers Rating Released by the Managers Association of Russia and Kommersant Publishing House

    Four NovaMedica executives are among the business leaders listed in the Top-1000 Russian Managers rating released annually by the Managers Association of Russia and Kommersant Publishing House.

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news